Napigen, Inc.
Napigen aims to harness the potentials of mitochondria and chloroplasts through proprietary organelle genome editing tools. Their technology offers opportunities in agriculture, human healthcare, and industrial biotechnology, with initial products focused on increasing crop yields and mitigating greenhouse gases to address global food security and environmental challenges.
Industries
Nr. of Employees
small (1-50)
Products
Organelle genome editing technology platform
A technology platform enabling targeted modification of mitochondrial and chloroplast genomes for applications in agriculture, human healthcare, and industrial biotechnology.
Gene-edited cytoplasmic male sterility (CMS) crop lines (research-stage)
Research-stage gene-edited crop lines with mitochondrial edits conferring cytoplasmic male sterility intended to enable hybrid seed production; one example (rice) has received a regulatory determination referenced on the site.
Organelle genome editing technology platform
A technology platform enabling targeted modification of mitochondrial and chloroplast genomes for applications in agriculture, human healthcare, and industrial biotechnology.
Gene-edited cytoplasmic male sterility (CMS) crop lines (research-stage)
Research-stage gene-edited crop lines with mitochondrial edits conferring cytoplasmic male sterility intended to enable hybrid seed production; one example (rice) has received a regulatory determination referenced on the site.
Expertise Areas
- Organelle genome editing
- Plant trait engineering and hybrid seed systems
- Preclinical mitochondrial gene therapy research
- Metabolic engineering for industrial biosynthesis
Key Technologies
- Polynucleotide-guided endonucleases for organelle editing
- Mitochondrial transformation
- Chloroplast transformation
- Model organism genetics (yeast, Chlamydomonas)